134 related articles for article (PubMed ID: 31309089)
1. Clinical significance of cell-free DNA as a prognostic biomarker in patients with diffuse large B-cell lymphoma.
Eskandari M; Manoochehrabadi S; Pashaiefar H; Zaimy MA; Ahmadvand M
Blood Res; 2019 Jun; 54(2):114-119. PubMed ID: 31309089
[TBL] [Abstract][Full Text] [Related]
2. Serum cell-free DNA concentration as a possible prognostic marker in newly diagnosed diffuse large B-cell lymphoma.
Shirouchi Y; Mishima Y; Takayama T; Minowa S; Ishihara Y; Tamba M; Hirano M; Onda N; Takeuchi K; Maruyama D
Biomed Res; 2022; 43(4):99-106. PubMed ID: 35989290
[TBL] [Abstract][Full Text] [Related]
3. Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas.
Hur JY; Kim YJ; Yoon SE; Son DS; Park WY; Kim SJ; Park D; Kim WS
Ann Hematol; 2020 Jun; 99(6):1293-1302. PubMed ID: 32296914
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma.
Chiu BC; Zhang Z; You Q; Zeng C; Stepniak E; Bracci PM; Yu K; Venkataraman G; Smith SM; He C; Zhang W
Blood Adv; 2019 Oct; 3(19):2790-2799. PubMed ID: 31570490
[TBL] [Abstract][Full Text] [Related]
5. Plasma cell-free DNA in paediatric lymphomas.
Mussolin L; Burnelli R; Pillon M; Carraro E; Farruggia P; Todesco A; Mascarin M; Rosolen A
J Cancer; 2013; 4(4):323-9. PubMed ID: 23678368
[TBL] [Abstract][Full Text] [Related]
6. miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B-cell lymphoma.
Wang X; Kan Y; Chen L; Ge P; Ding T; Zhai Q; Yu Y; Wang X; Zhao Z; Yang H; Liu X; Li L; Qiu L; Qian Z; Zhang H; Wang Y; Zhao H
Oncol Lett; 2020 May; 19(5):3487-3494. PubMed ID: 32269622
[TBL] [Abstract][Full Text] [Related]
7. Diffuse large B-cell lymphoma genotyping on the liquid biopsy.
Rossi D; Diop F; Spaccarotella E; Monti S; Zanni M; Rasi S; Deambrogi C; Spina V; Bruscaggin A; Favini C; Serra R; Ramponi A; Boldorini R; Foà R; Gaidano G
Blood; 2017 Apr; 129(14):1947-1957. PubMed ID: 28096087
[TBL] [Abstract][Full Text] [Related]
8. Cell-Free DNA as a Biomarker at Diagnosis and Follow-Up in 256 B and T-Cell Lymphomas.
Diez-Feijóo R; Andrade-Campos M; Gibert J; Sánchez-González B; Fernández-Ibarrondo L; Fernández-Rodríguez C; Garcia-Gisbert N; Camacho L; Lafuente M; Vázquez I; Colomo L; Salar A; Bellosillo B
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254810
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
10. Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies.
Decruyenaere P; Giuili E; Verniers K; Anckaert J; De Grove K; Van der Linden M; Deeren D; Van Dorpe J; Offner F; Vandesompele J
Front Oncol; 2023; 13():1221471. PubMed ID: 37954086
[TBL] [Abstract][Full Text] [Related]
11. Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review.
Arzuaga-Mendez J; Prieto-Fernández E; Lopez-Lopez E; Martin-Guerrero I; García-Ruiz JC; García-Orad A
Crit Rev Oncol Hematol; 2019 Jul; 139():7-15. PubMed ID: 31112884
[TBL] [Abstract][Full Text] [Related]
12. [Quantitation of Circulating Cell-free DNA in Patients with Lymphoma and Its Clinical Significance].
Chen YY; Guo SQ; Li YH; Wang DM; Liu X; Zhang YX; Wang SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1390-1396. PubMed ID: 27784363
[TBL] [Abstract][Full Text] [Related]
13. Direct quantification of cell-free, circulating DNA from unpurified plasma.
Breitbach S; Tug S; Helmig S; Zahn D; Kubiak T; Michal M; Gori T; Ehlert T; Beiter T; Simon P
PLoS One; 2014; 9(3):e87838. PubMed ID: 24595313
[TBL] [Abstract][Full Text] [Related]
14. The analysis of cell-free DNA concentrations and integrity in serum of initial and treated of lymphoma patients.
Wu J; Tang W; Huang L; Hou N; Wu J; Cheng X; Ma D; Qian P; Shen Q; Guo W; Peng W; Liu Y; Jiang C; Feng J
Clin Biochem; 2019 Jan; 63():59-65. PubMed ID: 30292543
[TBL] [Abstract][Full Text] [Related]
15. Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Dogs With Tumors.
Kim J; Bae H; Ahn S; Shin S; Cho A; Cho KW; Jung DI; Yu D
Front Vet Sci; 2021; 8():735682. PubMed ID: 34604371
[TBL] [Abstract][Full Text] [Related]
16. Loss of 5-hydroxymethylcytosine as a Poor Prognostic Factor for Primary Testicular Diffuse Large B-cell Lymphoma.
Shen Y; Wang L; Ou J; Wang B; Cen X
Int J Med Sci; 2022; 19(2):225-232. PubMed ID: 35165508
[No Abstract] [Full Text] [Related]
17. Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study.
Rivas-Delgado A; Nadeu F; Enjuanes A; Casanueva-Eliceiry S; Mozas P; Magnano L; Castrejón de Anta N; Rovira J; Dlouhy I; Martín S; Osuna M; Rodríguez S; Simó M; Pinyol M; Baumann T; Beà S; Balagué O; Delgado J; Villamor N; Setoain X; Campo E; Giné E; López-Guillermo A
Clin Cancer Res; 2021 Jan; 27(2):513-521. PubMed ID: 33122345
[TBL] [Abstract][Full Text] [Related]
18. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
Marchesi F; Regazzo G; Palombi F; Terrenato I; Sacconi A; Spagnuolo M; Donzelli S; Marino M; Ercolani C; Di Benedetto A; Blandino G; Ciliberto G; Mengarelli A; Rizzo MG
J Exp Clin Cancer Res; 2018 May; 37(1):95. PubMed ID: 29716630
[TBL] [Abstract][Full Text] [Related]
19. Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma.
Wedge E; Hansen JW; Garde C; Asmar F; Tholstrup D; Kristensen SS; Munch-Petersen HD; Ralfkiaer E; Brown P; Grønbaek K; Kristensen LS
Am J Hematol; 2017 Jul; 92(7):689-694. PubMed ID: 28378885
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
Huang H; Fan L; Fu D; Lin Q; Shen J
Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
